Latest & greatest articles for pregabalin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregabalin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregabalin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregabalin

61. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial (PubMed)

Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial Pain is a disabling symptom for patients with chronic pancreatitis (CP) and difficult to treat. Evidence from basic science and human studies indicates that pain processing by the central nervous system is abnormal and resembles that observed in patients with neuropathic pain disorders. We investigated whether agents used to treat patients with neuropathic pain are effective in CP.We conducted (...) a randomized, double-blind, placebo-controlled trial to evaluate the effects of the gabapentoid pregabalin as an adjuvant analgesic. We measured pain relief, health status, quality of life, and tolerability in 64 patients with pain from CP; they were randomly assigned to groups given increasing doses of pregabalin or placebo (control) for 3 consecutive weeks. The primary end point was pain relief, based on a visual analogue scale documented by a pain diary. Secondary end points included Patients' Global

2011 EvidenceUpdates

62. Safety and efficacy of pregabalin in patients with central post-stroke pain. (PubMed)

Safety and efficacy of pregabalin in patients with central post-stroke pain. Pregabalin has demonstrated efficacy in several forms of neuropathic pain, but its long-term efficacy in central post-stroke pain (CPSP) is unproven. We evaluated the efficacy and safety of pregabalin versus placebo in patients with CPSP. A 13-week, randomized, double-blind, multicenter, placebo-controlled, parallel group study of 150 to 600 mg/day pregabalin was conducted in patients aged ≥18 years with CPSP (...) . The primary efficacy endpoint was the mean pain score on the Daily Pain Rating Scale over the last 7 days on study drug up to week 12 or early termination visit. Secondary endpoints included other pain parameters and patient-reported sleep and health-related quality-of-life measures. A total of 219 patients were treated (pregabalin n=110; placebo n=109). A mean pain score at baseline of 6.5 in the pregabalin group and 6.3 in the placebo group reduced at endpoint to 4.9 in the pregabalin group and 5.0

2011 EvidenceUpdates

63. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial (PubMed)

Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial To date, published neuropathic pain randomized controlled trials of pregabalin have involved primarily diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). This multicenter trial evaluated pregabalin in a broader range of neuropathic pain etiologies.In this enriched enrollment randomized withdrawal trial, 256 patients received single blind, flexible (...) dose pregabalin for 4 weeks; stable concomitant analgesics were allowed. One hundred sixty-five (65%) had a ≥30% pain improvement and 157 were randomized and treated, double blind, to either continue pregabalin (n=80) or to receive placebo (n=77) for 5 weeks.Of the single blind responders randomized, 81% on placebo and 86% on pregabalin completed the double-blind phase. At the double-blind endpoint, mean (SD) pain scores were 2.9 (1.9) in the pregabalin group and 3.5 (1.7) in the placebo group (P

2011 EvidenceUpdates

64. Effective Dose of Peri-operative Oral Pregabalin as an Adjunct to Multimodal Analgesic Regimen in Lumbar Spinal Fusion Surgery (PubMed)

Effective Dose of Peri-operative Oral Pregabalin as an Adjunct to Multimodal Analgesic Regimen in Lumbar Spinal Fusion Surgery A prospective, randomized, controlled, and double-blind trial.To evaluate the effects of 2 different doses of perioperative pregabalin administration, twice on the day of surgery, on acute postoperative pain after spinal surgery.Besides its well-established role on neuropathic pain, pregabalin seems to be a promising adjunct to multimodal analgesic regimen following (...) surgery. No comprehensive data exist regarding the optimal dosage of pregabalin on reducing postoperative pain and opioid consumption in spinal surgery.Patients were randomly assigned to 1 of 3 groups. The placebo group (n = 28) received placebo capsules 1 hour before the anesthetic induction and 12 hours after surgery. The pregabalin groups received pregabalin 75 mg (P75 group, n = 28) or 150 mg (P150 group, n = 28), respectively at the same points. Assessed variables were total amount

2011 EvidenceUpdates

65. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder

A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder Boschen MJ CRD summary The review concluded that pregabalin was an effective treatment for generalised anxiety disorder compared to placebo. Given limitations in the review process as well as uncertain quality (...) of the included trials the authors conclusion may not be reliable. Authors' objectives To determine the efficacy of pregabalin for treatment of generalised anxiety disorder. Searching PubMed was searched up to December 2010 for relevant published peer-reviewed trials. Search terms were reported. References lists were searched. Study selection Randomised controlled trials (RCTs) that compared pregabalin with placebo for treatment of primary generalised anxiety disorder were eligible for inclusion in the review

2011 DARE.

66. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy (PubMed)

The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy We evaluated the efficacy of pregabalin in patients with chronic lumbosacral radiculopathy. This randomized, controlled, withdrawal trial included five phases: screening (4-18 days); run-in (4-10 days) to screen out placebo responders; single-blind (28 days) to identify pregabalin responders; double-blind to randomize responders to pregabalin or placebo (35 days (...) ); and final study medication taper (7 days). The primary endpoint was time to loss of response (LOR) during the double-blind phase (1-point increase in pain, discontinuation, or rescue-medication use). In the single-blind phase, 58% of patients had 30% pain reduction. In the double-blind phase, pregabalin (n=110) and placebo (n=107) groups did not differ significantly in time to LOR. Adverse events caused the discontinuation of 9.9% and 5.6% of pregabalin-treated and placebo-treated patients, respectively

2010 EvidenceUpdates

67. Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial (PubMed)

Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial Evidence suggests that the urogenital pain of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) may be neuropathic.This randomized, double-blind, placebo-controlled trial was conducted across 10 tertiary care centers in North America to determine whether pregabalin, which has been proved effective in other chronic pain syndromes, is effective in reducing CP/CPPS (...) symptoms. In 2006-2007, 324 men with pelvic pain for at least 3 of the previous 6 months were enrolled in this study. Men were randomly assigned to receive pregabalin or placebo in a 2:1 ratio and were treated for 6 weeks. Pregabalin dosage was increased from 150 to 600 mg/d during the first 4 weeks. The primary outcome was a 6-point decrease in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score. Multiple secondary outcomes were assessed.Of 218 men assigned

Full Text available with Trip Pro

2010 EvidenceUpdates

68. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome (PubMed)

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Duloxetine (DLX), milnacipran (MLN), and pregabalin (PGB) are the only drugs licensed by the US Food and Drug Administration (FDA) for fibromyalgia syndrome (FMS). Evidence on the comparative benefits and harms is still accruing. The authors searched MEDLINE, SCOPUS, Cochrane Central Register of Controlled Trials, and sought unpublished data from the databases of FDA, US National Institutes (...) ) efficacy of DLX, MLN, and PGB. Differences with regard to the occurrence of the key symptoms of FMS and to drug-specific adverse events may be relevant for the choice of medication.This article presents comparative data on the efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. The results can help clinicians in choosing medication since the 3 drugs have different effects on the key symptoms of fibromyalgia syndrome and differences in side effects, contraindications

2010 EvidenceUpdates

69. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin (PubMed)

A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin The aim of this randomized double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy, safety, and tolerability of pregabalin in combination with oxycodone or placebo, in patients with either postherpetic neuralgia (PHN) or painful diabetic neuropathy (PDN). After a 7-day washout period, 62 patients were randomized (...) to receive either oxycodone mixture 10 mg/day or placebo mixture for 1 week. Patients were then started on open-label pregabalin (75, 150, 300 and 600 mg/day) according to a forced titration dosing regimen, while continuing the same dosage of oxycodone or placebo for 4 weeks. The primary efficacy measure was a decrease in the pain-intensity score of at least 2cm and a pain score <4cm measured using a 10-cm visual analogue scale (VAS) following pregabalin dosage escalation and treatment for 4 weeks

2010 EvidenceUpdates

70. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports (PubMed)

Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports Meta-analysis of pregabalin trials in FM using company trial reports, which provide more detailed information about trials than published papers. FM is a common condition with a significant impact on quality of life.Reports of five high-quality randomized trials (3808 patients) of pregabalin in FM were obtained from Pfizer. Four trials (2754 patients) were of classical trial design and one (...) was an enriched enrolment randomized withdrawal design. Outcomes for meta-analysis from the four trials with classical design were pooled in an intention-to-treat analysis.Significant benefit of pregabalin over placebo was seen for a variety of outcomes including mean pain and sleep scores, the proportion of patients achieving at least 50% pain relief and most of the individual domains of short-form 36. Only a minority of patients achieve moderate or substantial pain relief. The proportions of patients

Full Text available with Trip Pro

2010 EvidenceUpdates

71. Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial (PubMed)

Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial Despite the enormous success of total knee arthroplasty (TKA), chronic neuropathic pain can develop postoperatively and is both distressing and difficult to treat once established. We hypothesized that perioperative treatment with pregabalin, a chronic pain medication, would reduce the incidence of postsurgical neuropathic pain.We performed a randomized, placebo (...) -controlled, double-blind trial of pregabalin (300 mg) administered before TKA and for 14 days after TKA (150-50 mg twice daily). Patients were screened for the presence of neuropathic pain at 3 and 6 mo postoperatively using the Leeds Assessment of Neuropathic Symptoms and Signs scale. Secondary outcomes included postsurgical recovery and rehabilitation measures, including knee range of motion, opioid consumption, postoperative pain scores, sleep disturbance, and time to discharge as well

Full Text available with Trip Pro

2010 EvidenceUpdates

72. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study

Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study Pregabalin and gabapentin in matched patients with peripheral neuropathic pain (...) was to assess the costs and benefits of pregabalin and gabapentin, for the treatment of adults with peripheral neuropathic pain, in routine medical practice. The authors concluded that pregabalin seemed to reduce the mean weekly intensity of pain more than gabapentin, with no significant difference in costs. The reporting and methods were satisfactory. The authors' conclusion appears to be appropriate, but highly uncertain. Type of economic evaluation Cost-effectiveness analysis, cost-utility analysis Study

2010 NHS Economic Evaluation Database.

73. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective

Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study compared oral pregabalin, an anticonvulsant medication, with venlafaxine extended release, for patients with generalised anxiety disorder. The authors concluded that pregabalin appeared to be cost

Full Text available with Trip Pro

2010 NHS Economic Evaluation Database.

74. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome

Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome Hauser W, Petzke F, Sommer C CRD summary The authors concluded that there was evidence of the short-term (up to six months) efficacy of duloxetine, milnacipran and pregabalin in fibromyalgia syndrome (...) ; the drugs differed in their effects on fibromyalgia syndrome domains and side-effects. The conclusions about the relative efficacy of drugs were not based on direct comparisons and may not be definitive. Authors' objectives To compare the efficacy and side-effects of duloxetine, milnacipran and pregabalin for the treatment of fibromyalgia syndrome. Searching MEDLINE, SCOPUS and Cochrane Central Register of Controlled Trials (CENTRAL) were searched to May 2009. Information was provided about the search

2010 DARE.

75. Randomised controlled trial: Pregabalin similar to lorazepam for alcohol withdrawal symptoms

Randomised controlled trial: Pregabalin similar to lorazepam for alcohol withdrawal symptoms Pregabalin similar to lorazepam for alcohol withdrawal symptoms | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregabalin similar to lorazepam for alcohol withdrawal symptoms Article Text Therapeutics Randomised controlled trial Pregabalin similar to lorazepam for alcohol withdrawal symptoms Giovanni Addolorato 1 , Lorenzo Leggio 1 , 2

2010 Evidence-Based Medicine (Requires free registration)

76. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective

Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective Choy E, Richards S, Bowrin K, Watson P, Lloyd A, Sadosky A, Zlateva G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of pregabalin versus placebo, duloxetine, gabapentin, tramadol, or amitriptyline, for the treatment of fibromyalgia. Pregabalin 450mg was consistently more cost-effective than pregabalin 300mg and both doses were cost-effective over placebo and duloxetine, for a population with severe disease. The study

2010 NHS Economic Evaluation Database.

77. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial (PubMed)

Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial To compare the efficacy and safety of pregabalin and amitriptyline in alleviating pain associated with diabetic peripheral neuropathy.A randomized, double-blind, crossover, active-control, clinical trial with variable dose titration was carried out (n = 51). Amitriptyline orally, at doses of 10, 25 and 50 mg at night-time and pregabalin orally, at doses of 75, 150 and 300 mg twice daily (...) , by optional titration was used. Each drug treatment was of 5 weeks. There was a placebo washout period for 3 weeks between the two drugs. Assessment for pain relief, overall improvement and adverse events were carried out.Good, moderate and mild pain relief were noted in 21 (48%), 6 (13%) and 7 (15%) patients on pregabalin and 15 (34%), 5 (11%) and 12 (27%) patients on amitriptyline, respectively, by patient's global assessment of efficacy and safety. Patient and physician's global assessment, McGill pain

2010 EvidenceUpdates

78. Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis

Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

79. Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review

Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

80. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis

Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 NHS Economic Evaluation Database.